Inhibrx Biosciences, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company with two principal clinical programs, ozekibart (INBRX-109) and INBRX-106. Form 8-K reports furnish financial results, Regulation FD presentations, and clinical updates covering oncology studies in chondrosarcoma, colorectal cancer, Ewing sarcoma, head and neck squamous cell carcinoma, and non-small cell lung cancer.
The company’s proxy materials describe annual meeting matters, board elections, executive compensation and equity incentive governance. Its filings also identify Inhibrx Biosciences as an emerging growth company and provide formal disclosures on operating results, pipeline development, capital resources, risk factors, and the completed 2024 separation from Inhibrx, Inc.
Inhibrx Biosciences, Inc. (INBX) reported that director Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust dated June 4, 2012, sold a total of 1,500 shares of common stock in open market or private transactions on September 11, 14, and 15, 2026 at prices between $105.05 and $111.78 per share. The sales were reported as indirect ownership transactions by the trust, for which Ms. Manhard may be deemed to beneficially own the securities as trustee.
Inhibrx Biosciences, Inc. (INBX) is the issuer for a Rule 144 notice filed on behalf of director Kimberly Manhard, covering planned sales of company common stock. The notice lists 500 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $52,525.00 and 14,717,660 shares outstanding as of September 15, 2026.
The filing also reports that, during the prior three months, the Kimberly Joan Manhard Revocable Trust sold four blocks of 500 common shares each on September 8, 9, 11, and 14, 2026, for aggregate amounts of $57,570.00, $57,897.50, $55,887.50, and $55,130.00, respectively. The notice states that these sales occurred in the trust, of which Kimberly Manhard is a trustee.
Inhibrx Biosciences, Inc. (INBX) discloses that director Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust and using Fidelity Brokerage Services LLC, has filed a notice to sell 500 shares of common stock. The shares were acquired on August 28, 2024 in an open market purchase and are to be sold for cash, with recent prior sales of 500-share blocks reported over the past three months.
Inhibrx Biosciences, Inc. (INBX) has a Rule 144 notice filed on behalf of director Kimberly Manhard, covering a proposed sale of 500 shares of common stock held in the Kimberly Joan Manhard Revocable Trust. The notice reports that Inhibrx had 14,717,660 shares outstanding as of September 11, 2026. The trust also sold 500 shares for $57,570.00 on September 8, 2026 and 500 shares for $57,897.50 on September 9, 2026, indicating recent selling activity by the same trust account.
Inhibrx Biosciences, Inc. (INBX) director Kimberly Manhard reported indirect sales of common stock held by the Kimberly Joan Manhard Revocable Trust, Dtd 6/4/2012. The trust sold 500 shares on September 8, 2026 at $115.14 per share and 500 shares on September 9, 2026 at $115.795 per share. Manhard, as trustee, may be deemed to indirectly beneficially own the trust’s shares, and no Rule 10b5-1 trading plan is reported.
Inhibrx Biosciences, Inc. (INBX) received a Rule 144 notice relating to a proposed sale of its common stock. A person identified as Kimberly Manhard, through the Kimberly Joan Manhard Revocable Trust, has filed to sell 500 shares of Inhibrx Biosciences common stock through Fidelity Brokerage Services LLC.
Inhibrx Biosciences, Inc. (INBX) is the issuer for which a notice has been filed to permit the potential resale of its common stock under Rule 144 on behalf of Kimberly Manhard. The notice covers 500 shares of common stock held in the Kimberly Joan Manhard Revocable Trust. The filing lists an aggregate market value of $57,570.00 for these shares and identifies Fidelity Brokerage Services LLC as the broker, with the notice dated September 8, 2026.
Inhibrx Biosciences, Inc. (INBX) director Jon Faiz Kayyem reported that The Jon F. Kayyem and Paige Gates-Kayyem Family Trust purchased 5,000 shares of common stock on September 8, 2026 at a weighted-average price of $113.52 per share in open-market transactions, with prices ranging from $113.30 to $113.55.
After this purchase, that Family Trust held 424,360 shares indirectly attributed to Kayyem, for which he disclaims beneficial ownership except for any indirect pecuniary interest. Additional indirect holdings reported include 250,000 shares in the Jon Faiz Kayyem Revocable Trust, 250,000 shares in the Paige Gates-Kayyem Revocable Trust, and 69,843 shares in custodial accounts for each of two minor children.
Inhibrx Biosciences, Inc. (INBX) director Douglas Forsyth reported an open-market purchase of company stock through a family trust. On September 8, 2026, the Forsyth Family Trust bought 2,500 shares of common stock at a weighted-average price of $114.6469 per share.
The shares are held indirectly via the Forsyth Family Trust Dated July 20, 2001, of which Forsyth is a trustee and may be deemed to indirectly beneficially own the securities. Following this transaction, the trust held 227,064 shares of Inhibrx Biosciences common stock. The price reflects multiple trades between $114.36 and $114.689 per share, and no Rule 10b5-1 trading plan is reported.
Inhibrx Biosciences, Inc. (INBX) reported that Chief Executive Officer and director Mark P. Lappe, through the Lappe Family Trust, purchased a total of 25,000 shares of common stock on September 8, 2026 in multiple open-market transactions at weighted-average prices around $99–$112 per share. The filing also reports additional indirect holdings in a family trust and a Roth IRA.